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Introduction 
Recent epidemiological studies revealed that diabetes mellitus accentuates the age-dependent decline of cognitive function [1] which is related to reduction of 
hippocampal volume [2], a brain structure involved in learning and memory processing. Streptozotozin can be used to experimental type 1 diabetes in rats, characterized 
by chronic hyperglycaemia, deficits in learning and memory and impaired hippocampal function [3], as in human diabetes. The aim of the study was to measure the 
neurochemical profile and the kinetics of glucose transport in the hippocampus of streptozotocin (STZ)-induced diabetic rats using non-invasive 1H NMR spectroscopy.  
 
Materials and Methods   
Animal preparation: Type 1 diabetes was induced in Sprague-Dawley rats (8 weeks old) by i.p. 
injection of STZ (65 mg/kg, prepared in sodium citrate buffer 10 mM, pH 4.5), which induced 
sustained levels of blood glucose above 300 mg/dL after 3 days [4], and maintained for 1 month 
with food and water ad libitum. Age-matched untreated rats were used as controls. The rats were 
anaesthetized using 2 % isoflurane in oxygen gas for surgery, and then were intubated and 
ventilated with a pressure-driven ventilator. Catheters were inserted into the femoral artery for 
monitoring blood gases, glucose and arterial blood pressure, and into the femoral vein for 
intravenous infusion of α-chloralose, glucose and/or insulin. After surgery the anesthesia was 
switched to α-chloralose (i.v. bolus of 80 mg/kg and infusion of 25 mg kg−1h−1). D-glucose [20 % 
(w/v) solution] was infused at a rate adjustable to the concomitantly measured plasma glucose 
concentrations to achieve stable target glycemic levels. Insulin (1 U/mL solution) was infused to 
reduce glycaemia of STZ-treated rats. NMR measurements were performed after each glucose level 
had been stable for more than 15 minutes. The body temperature was maintained at 37 °C. the 
arterial PCO2 between 35 and 45 mm Hg and the arterial pH at 7.40.  
NMR spectroscopy: All experiments were carried out on an actively-shielded 9.4 T, 31 cm scanner 
(Varian/Magnex) using a homebuilt 10 mm 1H quadrature surface coil. Shimming was performed 
with FASTMAP, and 1H NMR spectra were acquired from an 18 µL voxel positioned in the left 
hippocampus using SPECIAL [5] with TE of 2.8 ms and TR of 4 s. The spectral analysis was 
carried out using LCModel [6]. 
 
Results and Discussion 
1H NMR spectra obtained directly showed elevated glucose concentration (at 5.23 ppm) in the 
hippocampus of the diabetic rat, which returned to control levels upon normalization of glycaemia 
(Fig. 1), consistent with unaltered hippocampal glucose transport compared to controls (Fig. 2). 
STZ-treated animals displayed signficantly altered neurochemical profile in the hippocampus (Fig. 
2), e.g. increased glutamate (Glu), myo-inositol (Ins), glycerophosphocholine (GPC), 
phosphocholine (PCho), taurine (Tau), β-hidroxybutyrate (bHB), scyllo-inositol (Scyllo) and total 
creatine (Cr+PCr) and decreased glutathione (GSH) and N-acetylaspartylglutamate (NAAG) 
concentrations. Glycaemic normalization restored all but the concentrations of myo-Inositol and 
phosphocholine, suggesting that the main effect of diabetes on brain metabolites is due to 
osmolarity dysregulation that is counterbalanced namely by increased myo-inositol, taurine and 
total creatine. We conclude that (a) chronic hyperglycemia does not alter brain glucose 
transport/content and (b) glycemia restoration immediately normalizes most neurochemical 
alterations.  
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Fig. 1. in vivo 1H NMR spectra of the rat hippocampus at 9.4 
T, from Control (top) and STZ-treated rats before (center) and 
after (bottom) glycaemic normalization with insulin infusion. 
Fig. 2. Hippocampal glucose concentration as function of plasma glucose (left panel) and metabolic profile (right panel) in control (n=6) and 
STZ-treated rats (n=4) under hyperglycaemia and after glycaemic normalization. From these three experimental groups, glycaemia was 4.9±0.5 
mM, 37.6±5.9 mM and 6.2±1.2 mM, respectively. Results are presented as mean±SEM and were analyzed with the Student’s t test (* P<0.05). 
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